OpenNashEarnings

Waters (WAT) · Life Sciences

Waters Q2 2026 earnings: summary, key numbers & outlook

Results filed 4 Aug 2026 · Quarter ended 4 Jul 2026

Slides (33 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Waters' first full quarter owning BD's biosciences and diagnostics businesses showed mid-single-digit growth there, while a broadening instrument replacement recovery lifted its core analytical business.

Waters completed its first full quarter with the Biosciences and Diagnostic Solutions businesses acquired from BD, and they grew 4% on a comparable basis, faster than management expected. Its core Analytical Sciences business saw instrument and chemistry consumables demand strengthen, with Pharma and Academic & Government customers leading and previously lagging segments returning to growth. Management credits a 180-day plan covering pricing, reagent compliance and share recovery in flow cytometry research products.

Management is steering toward revenue synergies from the acquisition, such as service attachment, e-commerce, cross-selling and new products. It is also pursuing replacement of aging flow cytometry and blood culture instruments, with new launches starting in the second half. The main tension is execution: integration, cost actions and a continued decline in China diagnostics must deliver while the market recovery holds. Management is raising every component of full-year guidance.

Slides & documents

Open the slide deck (PDF, 33 pages) ↗

Waters Q2 2026 slide deck, page 1Waters Q2 2026 slide deck, page 2Waters Q2 2026 slide deck, page 3Waters Q2 2026 slide deck, page 4Waters Q2 2026 slide deck, page 5Waters Q2 2026 slide deck, page 6

Showing the first 6 of 33 pages.

From Waters investor relations

SEC filing

Key numbers

Total revenue · GAAP
$1.645 billion

up 113% from a year ago

Net (loss) income · GAAP
-$136.0M

compared with income of $147 million a year ago

Diluted EPS · GAAP
($1.39)

compared with $2.47 a year ago

Adjusted EPS · non-GAAP
$3.05

up 3% from $2.95 a year ago

Adjusted gross margin · non-GAAP
54.0%

Operating (loss) income · GAAP
-86.0M

compared with income of $188 million a year ago

Adjusted operating margin · non-GAAP
25.0%

compared with 29.1% a year ago

Net cash provided by operating activities · GAAP
200.0M

compared with $41 million a year ago

Segment or metricValueChange
Analytical Sciences Division$669.0Mup 7% as reported
Biosciences Division$368.0Mup 3% on a prior year comparable basis
Advanced Diagnostics Division$521.0Mup 7% on a prior year comparable basis
Materials Sciences Division$87.0Mup 6% as reported
Diagnostic Solutions$449.0Mcompared with $425 million in the prior year comparable period
Clinical Business Unit$72.0Mcompared with $62 million a year ago
ASD instrument revenue$240.0Mup 8% in constant currency
Where each number comes from
  • Total revenue: “Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.”
  • Net (loss) income: “Net (loss) income | $(136) | $147 | $(208) | $268 Net (loss) income per basic common share”
  • Diluted EPS: “GAAP EPS of ($1.39); Adjusted EPS of $3.05 landed at the high end of the guidance range, as early cost actions offset unfavorable foreign exchange translation.”
  • Adjusted EPS: “Adjusted EPS for the second quarter of 2026 grew 3% to $3.05, compared to $2.95 for the second quarter of 2025.”
  • Adjusted gross margin: “Adjusted Gross & Operating Margin 889 54.0% 411 25.0%”
  • Operating (loss) income: “Operating (loss) income | (86) | 188 | (134) | 340 Other (expense) income, net”
  • Adjusted operating margin: “Adjusted Non-GAAP | $756 | $357 | $121 | $411 | 25.0% | $(55) | $356 | $(56) | $301 | $3.05”
  • Net cash provided by operating activities: “Net cash provided by operating activities | 200 | 41 | 198 | 301 Cash flows from investing activities”
  • Analytical Sciences Division: “Analytical Sciences Division (ASD) | $669 | $627 | 7% Biosciences Division (WBD) | 368 | — | **”
  • Biosciences Division: “Biosciences Division (WBD) | 368 | — | ** Advanced Diagnostics Division (ADx) | 521 | 62 | 733%”
  • Advanced Diagnostics Division: “Advanced Diagnostics Division (ADx) | 521 | 62 | 733% Materials Sciences Division (MSD) | 87 | 82 | 6%”
  • Materials Sciences Division: “Materials Sciences Division (MSD) | 87 | 82 | 6% Total Revenue | $1,645 | $771 | 113%”
  • Diagnostic Solutions: “The Diagnostic Solutions business delivered reported revenue of $449 million in the quarter, compared to $425 million for the prior year comparable period.”
  • Clinical Business Unit: “The Clinical Business Unit delivered reported revenue of $72 million in the quarter, compared to $62 million for the second quarter of 2025.”
  • ASD instrument revenue: “ASD Instrument Revenue | $240 | $229 | 5% Currency Translation Impact | (3%) Constant Currency ASD Instrument Revenue Growth | 8%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$1.6B+113.3%+29.8%
Operating income-$86.0M—−83.0%
Net income-$136.0M—−88.9%
Diluted EPS-$1.39—−59.8%
Free cash flow$153.0M+750.0%—
Operating margin-5.2%−29.6 pts−1.5 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Total reported revenuethird quarter of 2026$1.745 billion to $1.762 billion
Organic constant currency revenue growththird quarter of 20268% to 10%
Adjusted EPSthird quarter of 2026$3.95 to $4.05
Total reported revenuefull-year 2026$6.415 billion to $6.476 billion
Organic constant currency revenue growthfull-year 20267.0% to 9.0%
Adjusted EPSfull-year 2026$14.45 to $14.65

Key takeaways

  1. BD businesses accelerated under Waters' 180-day plan

    Biosciences and Diagnostic Solutions grew 4% on a comparable basis, which management says is a faster-than-expected move to mid-single-digit growth. The plan focuses on urgency, pricing and reagent compliance, and regaining share in flow research products.

  2. Instrument recovery has broadened beyond Pharma

    Analytical Sciences instruments grew 8% in constant currency, with chemistry consumables up double digits. Pharma grew 11% and Academic & Government 11%, and previously lagging segments are returning to growth.

  3. New flow cytometry and blood culture products drive replacement

    Waters introduced the FACSDiscover A7 spectral cell analyzer and began BACTEC FXI placements. It says 10,000+ of ~25,000 flow cytometry installed-base units have aged, and 12,000+ BACTEC systems are past due for replacement, with the opportunity starting in 2H26.

  4. Revenue synergies are the next phase of integration

    Management says the acquisition is moving from operational fixes to a first tranche of revenue synergies. These include service plan attachment, e-commerce, cross-selling and new bioseparations products, with taking flow into pharma QC and MALDI-TOF later.

  5. Full-year guidance raised on broader market strength

    Waters raised every component of its 2026 outlook, citing better-than-expected results and strengthening end markets. China microbiology remains a drag, declining 13% though better than expected.

Charts

Revenue$1.6B+113.3% y/yQ2 2026
Q4 2024: $872.7MQ4 ’24$872.7MQ1 2025: $661.7MQ1 ’25$661.7MQ2 2025: $771.3MQ2 ’25$771.3MQ3 2025: $799.9MQ3 ’25$799.9MQ4 2025: $932.4MQ4 ’25$932.4MQ1 2026: $1.3BQ1 ’26$1.3BQ2 2026: $1.6BQ2 ’26$1.6BQ3 2026: $1.8BQ3 ’26$1.8B
Data
Q4 2024$872.7M
Q1 2025$661.7M
Q2 2025$771.3M
Q3 2025$799.9M
Q4 2025$932.4M
Q1 2026$1.3B
Q2 2026$1.6B
Q3 2026$1.8B
Diluted EPS (GAAP)-$1.39Q2 2026
Q4 2024: $3.88Q4 ’24$3.88Q1 2025: $2.03Q1 ’25$2.03Q2 2025: $2.47Q2 ’25$2.47Q3 2025: $2.50Q3 ’25$2.50Q4 2025: $3.77Q4 ’25$3.77Q1 2026: -$0.87Q1 ’26-$0.87Q2 2026: -$1.39Q2 ’26-$1.39Q3 2026: $0.82Q3 ’26$0.82
Data
Q4 2024$3.88
Q1 2025$2.03
Q2 2025$2.47
Q3 2025$2.50
Q4 2025$3.77
Q1 2026-$0.87
Q2 2026-$1.39
Q3 2026$0.82

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin-5.2%−29.6 pts y/yQ2 2026
Q4 2024: 33.5%Q4 ’2433.5%Q1 2025: 22.9%Q1 ’2522.9%Q2 2025: 24.4%Q2 ’2524.4%Q3 2025: 24.0%Q3 ’2524.0%Q4 2025: 29.0%Q4 ’2529.0%Q1 2026: -3.7%Q1 ’26-3.7%Q2 2026: -5.2%Q2 ’26-5.2%Q3 2026: 7.2%Q3 ’267.2%
Data
Q4 202433.5%
Q1 202522.9%
Q2 202524.4%
Q3 202524.0%
Q4 202529.0%
Q1 2026-3.7%
Q2 2026-5.2%
Q3 20267.2%
Free cash flow$153.0M+750.0% y/yQ2 2026
Q1 2025: $234.0MQ1 ’25$234.0MQ2 2025: $18.0MQ2 ’25$18.0MQ3 2025: $162.0MQ3 ’25$162.0MQ4 2025: $125.8MQ4 ’25$125.8MQ1 2026: -$42.0MQ1 ’26-$42.0MQ2 2026: $153.0MQ2 ’26$153.0MQ3 2026: $54.0MQ3 ’26$54.0M
Data
Q1 2025$234.0M
Q2 2025$18.0M
Q3 2025$162.0M
Q4 2025$125.8M
Q1 2026-$42.0M
Q2 2026$153.0M
Q3 2026$54.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What changed at Waters' newly acquired BD businesses this quarter?

In their first full quarter under Waters, the Biosciences and Diagnostic Solutions businesses grew 4% on a comparable basis, ahead of guidance. Management credits a 180-day plan covering pricing, reagent compliance and regaining flow research share.

Where is demand coming from in Waters' core analytical business?

Pharma grew 11% in constant currency, driven by instrument replacement, GLP-1s, generics and biologics, and Academic & Government grew 11%. Biotech and CRO spending also improved, and lagging customer segments are returning to growth.

Which new products is Waters launching?

Waters introduced the FACSDiscover A7 spectral flow cytometry analyzer and began placing the BACTEC FXI blood culture system, launched in 2026. Both target instrument replacement opportunities starting in the second half.

What are the main competitive or risk factors in diagnostics?

Microbiology in China declined 13%, though better than expected, while microbiology outside China grew 6%. Integration execution and realizing synergies are also flagged as risks.

How is management positioning Waters for growth beyond 2026?

It points to moving from operational improvements to revenue synergies such as service attachment, e-commerce and cross-selling. It also sees reshoring as a 2027-30 tailwind, with 37 of 76 tracked U.S. expansion sites under construction.